Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Littlejohn

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
International Journal of Rheumatic Diseases|February 17, 2017
Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT studyPaul Bird, Dave Nicholls, Rina Barrett, et al.
International Journal of Rheumatic Diseases|June 4, 2014
Australian and New Zealand evidence-based recommendations for pain management by pharmacotherapy in adult patients with inflammatory arthritisBethan L Richards, Samuel Whittle, Rachelle Buchbinder, et al.
Clinical Rheumatology|November 26, 2021
Prevalence of sleep disturbance and the association between poor disease control in people with ankylosing spondylitis within the Australian clinical setting (ASLEEP study): a real-world observational study using the OPAL datasetKathleen Tymms, Belinda E Butcher, Tracey L Sletten, et al.
The Journal of Rheumatology|July 3, 2015
Patients with Rheumatoid Arthritis in the Australian OPAL Cohort Show Significant Improvement in Disease Activity over 5 Years: A Multicenter Observational StudyGeoffrey Littlejohn, Lynden Roberts, Paul Bird, et al.
Rheumatology and Therapy|January 5, 2025
Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid ArthritisPeter Youssef, Sabina Ciciriello, Talib Tahir, et al.
Clinical Rheumatology|March 8, 2024
Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in AustraliaGeoffrey Littlejohn, Joanna Leadbetter, Belinda E Butcher, et al.
Rheumatology and Therapy|September 13, 2025
Correction: Real‑World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid ArthritisPeter Youssef, Sabina Ciciriello, Talib Tahir, et al.
International Journal of Rheumatology|June 21, 2017
The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology PracticeLynden Roberts, Kathleen Tymms, Julien de Jager, et al.
International Journal of Rheumatic Diseases|February 5, 2025
The Relationship Between Patient-Reported Quality of Life and Physician-Derived Clinical Outcomes in Rheumatoid Arthritis in the Australian OPAL DatasetGeoffrey Littlejohn, Nithila Anbumurali, Catherine O'Sullivan, et al.
ACR Open Rheumatology|June 12, 2023
Comparative Effectiveness of First-Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data SetSabina Ciciriello, Geoffrey Littlejohn, Tamas Treuer, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
International Journal of Rheumatic Diseases|February 17, 2017
Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT studyPaul Bird, Dave Nicholls, Rina Barrett, et al.
International Journal of Rheumatic Diseases|June 4, 2014
Australian and New Zealand evidence-based recommendations for pain management by pharmacotherapy in adult patients with inflammatory arthritisBethan L Richards, Samuel Whittle, Rachelle Buchbinder, et al.
Clinical Rheumatology|November 26, 2021
Prevalence of sleep disturbance and the association between poor disease control in people with ankylosing spondylitis within the Australian clinical setting (ASLEEP study): a real-world observational study using the OPAL datasetKathleen Tymms, Belinda E Butcher, Tracey L Sletten, et al.
The Journal of Rheumatology|July 3, 2015
Patients with Rheumatoid Arthritis in the Australian OPAL Cohort Show Significant Improvement in Disease Activity over 5 Years: A Multicenter Observational StudyGeoffrey Littlejohn, Lynden Roberts, Paul Bird, et al.
Rheumatology and Therapy|January 5, 2025
Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid ArthritisPeter Youssef, Sabina Ciciriello, Talib Tahir, et al.
Clinical Rheumatology|March 8, 2024
Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in AustraliaGeoffrey Littlejohn, Joanna Leadbetter, Belinda E Butcher, et al.
Rheumatology and Therapy|September 13, 2025
Correction: Real‑World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid ArthritisPeter Youssef, Sabina Ciciriello, Talib Tahir, et al.
International Journal of Rheumatology|June 21, 2017
The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology PracticeLynden Roberts, Kathleen Tymms, Julien de Jager, et al.
International Journal of Rheumatic Diseases|February 5, 2025
The Relationship Between Patient-Reported Quality of Life and Physician-Derived Clinical Outcomes in Rheumatoid Arthritis in the Australian OPAL DatasetGeoffrey Littlejohn, Nithila Anbumurali, Catherine O'Sullivan, et al.
ACR Open Rheumatology|June 12, 2023
Comparative Effectiveness of First-Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data SetSabina Ciciriello, Geoffrey Littlejohn, Tamas Treuer, et al.
Pageof 5